A multicentre double-blind, placebo-controlled, randomised, parallel-group study to evaluate the safety and efficacy of BGC20-1259 in patients with mild to moderate probable Alzheimer’s Disease To evaluate the efficacy of BGC20-1259 (12.5 mg, 25 mg and 50 mg qd) administered for 6 months versus matched placebo

• Country None
• organs None
• Specialty None

A randomised double-blind placebo-controlled phase IIa study of orally administered BGC20-0134 in patients with relapsing-remitting multiple sclerosis (RRMS) General Aim: To assess the efficacy and safety of BGC20-0134 in patients with RRMS treated for 24 weeks in in the double-blind period and for a further 24 weeks in the open-label period Primary Endp...

• Country None
• organs None
• Specialty None

A multinational, multi-centre, randomised, double-blind, placebo-controlled, 3-way crossover study in migraine patients, treated with two doses of BGC20-1531 and placebo • To evaluate the effect of BGC20-1531 on headache response, defined as a decrease of headache from severe or moderate to mild or none at 2 hours post-dose without the use of rescue medication.

• Country None
• organs None
• Specialty None